Logo for Abliva

Abliva Investor Relations Material

Latest events

Logo for Abliva

Status Update

Logo for Abliva

Q4 2023

23 Feb, 2024
Logo for Abliva

Q3 2023

17 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Abliva

Access all reports
Abliva AB, engages in the research and development of mitochondrial medicine for the treatment of neurodegenerative diseases in Sweden. The company's lead candidate is NGM282, an engineered hormone that drives expression of the human glucokinase gene, which is in Phase 2b/3a clinical study as a once-weekly treatment for type 2 diabetes and has completed Phase 1b/2a clinical study to treat non-alcoholic steatohepatitis; and completed a Phase 2 clinical study in patients with primary biliary cholangitis disease.